Influence of intra-tumoral heterogeneity on the evaluation of BCL2, E-cadherin, EGFR, EMMPRIN, and Ki-67 expression in tissue microarrays from breast cancer

References

• Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998;4:844–847.
   PubMed Web of Science ®Google Scholar
• Bubendorf L, Nocito A, Moch H, et al. Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughput in situ studies. J Pathol. 2001;195:72–79.
   PubMed Web of Science ®Google Scholar
• Horvath L, Henshall S. The application of tissue microarrays to cancer research. Pathology. 2001;33:125–129.
   PubMed Web of Science ®Google Scholar
• Simon R, Sauter G. Tissue microarrays for miniaturized high-throughput molecular profiling of tumors. Exp Hematol. 2002;30:1365–1372.
   PubMed Web of Science ®Google Scholar
• Kyndi M, Sorensen FB, Knudsen H, et al. Tissue microarrays compared with whole sections and biochemical analyses. A subgroup analysis of DBCG 82 b&c. Acta Oncol. 2008;47:591–599.
   PubMed Web of Science ®Google Scholar
• Kyndi M, Sorensen FB, Knudsen H, et al. Carbonic anhydrase IX and response to postmastectomy radiotherapy in high-risk breast cancer: a subgroup analysis of the DBCG82 b and c trials. Breast Cancer Res. 2008;10:R24.
   PubMed Web of Science ®Google Scholar
• Callagy GM, Webber MJ, Pharoah PD, et al. Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer. BMC Cancer. 2008;8:153
   PubMed Web of Science ®Google Scholar
• Eom YH, Kim HS, Lee A, et al. BCL2 as a subtype-specific prognostic marker for breast cancer. J Breast Cancer. 2016;19:252–260.
   PubMed Web of Science ®Google Scholar
• Callagy GM, Pharoah PD, Pinder SE, et al. Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index. Clin Cancer Res. 2006;12:2468–2475.
   PubMed Web of Science ®Google Scholar
• Gould Rothberg BE, Bracken MB. E-cadherin immunohistochemical expression as a prognostic factor in infiltrating ductal carcinoma of the breast: a systematic review and meta-analysis. Breast Cancer Res Treat. 2006;100:139–148.
   PubMed Web of Science ®Google Scholar
• Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10:5367–5374.
   PubMed Web of Science ®Google Scholar
• Nakai K, Hung MC, Yamaguchi H. A perspective on anti-EGFR therapies targeting triple-negative breast cancer. Am J Cancer Res. 2016;6:1609–1623.
   PubMed Web of Science ®Google Scholar
• Zhao S, Ma W, Zhang M, et al. High expression of CD147 and MMP-9 is correlated with poor prognosis of triple-negative breast cancer (TNBC) patients. Med Oncol. 2013;30:335–012-0335-4.
   PubMed Web of Science ®Google Scholar
• Grass GD, Tolliver LB, Bratoeva M, et al. CD147, CD44, and the epidermal growth factor receptor (EGFR) signaling pathway cooperate to regulate breast epithelial cell invasiveness. J Biol Chem. 2013;288:26089–26104.
   PubMed Web of Science ®Google Scholar
• Pathmanathan N, Balleine RL. Ki67 and proliferation in breast cancer. J Clin Pathol. 2013;66:512–516.
   PubMed Web of Science ®Google Scholar
• Liu Y, Xin T, Jiang QY, et al. CD147, MMP9 expression and clinical significance of basal-like breast cancer. Med Oncol. 2013;30:366.
   PubMed Web of Science ®Google Scholar
• Howat WJ, Blows FM, Provenzano E, et al. Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium. J Pathol Clin Res. 2014;1:18–32.
   PubMedGoogle Scholar
• Meijnen P, Peterse JL, Antonini N, et al. Immunohistochemical categorisation of ductal carcinoma in situ of the breast. Br J Cancer. 2008;98:137–142.
   PubMed Web of Science ®Google Scholar
• Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2013. Ann Oncol. 2013;24:2206–2223.
   PubMed Web of Science ®Google Scholar
• Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159–174.
   PubMed Web of Science ®Google Scholar
• Chhieng DC, Frost AR, Niwas S, et al. Intratumor heterogeneity of biomarker expression in breast carcinomas. Biotech Histochem. 2004;79:25–36.
   PubMed Web of Science ®Google Scholar
• Nassar A, Radhakrishnan A, Cabrero IA, et al. Intratumoral heterogeneity of immunohistochemical marker expression in breast carcinoma: a tissue microarray-based study. Appl Immunohistochem Mol Morphol. 2010;18:433–441.
   PubMedGoogle Scholar
• Simon R, Mirlacher M, Sauter G. Tissue microarrays. BioTechniques. 2004;36:98–105.
   PubMed Web of Science ®Google Scholar
• Watanabe A, Cornelison R, Hostetter G. Tissue microarrays: applications in genomic research. Expert Rev Mol Diagn. 2005;5:171–181.
   PubMed Web of Science ®Google Scholar
• Denkert C, Budczies J, von Minckwitz G, et al. Strategies for developing Ki67 as a useful biomarker in breast cancer. Breast. 2015;24 Suppl 2:S67–S72.
   PubMed Web of Science ®Google Scholar
• Muftah AA, Aleskandarany MA, Al-Kaabi MM, et al. Ki67 expression in invasive breast cancer: the use of tissue microarrays compared with whole tissue sections. Breast Cancer Res Treat. 2017;164:341–348.
   PubMed Web of Science ®Google Scholar
• Batistatou A, Televantou D, Bobos M, et al. Evaluation of current prognostic and predictive markers in breast cancer: a validation study of tissue microarrays. Anticancer Res. 2013;33:2139–2145.
   PubMed Web of Science ®Google Scholar
• Varga Z, Diebold J, Dommann-Scherrer C, et al. How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss Working Group of Breast- and Gynecopathologists. PLoS One. 2012;7:e37379.
   PubMed Web of Science ®Google Scholar
• Dowsett M, Nielsen TO, A'Hern R, et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst. 2011;103:1656–1664.
   PubMed Web of Science ®Google Scholar
• Ilyas M, Grabsch H, Ellis IO, et al. Guidelines and considerations for conducting experiments using tissue microarrays. Histopathology. 2013;62:827–839.
   PubMed Web of Science ®Google Scholar
• Camp RL, Neumeister V, Rimm DL. A decade of tissue microarrays: progress in the discovery and validation of cancer biomarkers. J Clin Oncol. 2008;26:5630–5637.
   PubMed Web of Science ®Google Scholar
• Altman DG, McShane LM, Sauerbrei W, et al. Reporting Recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. PLoS Med. 2012;9:e1001216.
   PubMed Web of Science ®Google Scholar